Pharmaceutical intermediates
Nemorexant Intermediates
8 pharmaceutical intermediates for Nemorexant. Indication: Sleep Initiation and Maintenance Disorders; Insomnia.
About Nemorexant
- Originator
- Actelion Pharmaceuticals Ltd
- Indication
- Sleep Initiation and Maintenance Disorders; Insomnia
- Approved Date
- 04/07/2022
- NCE Patent
- 04/07/2027
- DS/DP
- 06/12/2033
Available intermediates
8 intermediates currently listed for Nemorexant. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2-Methyl-L-proline Methyl ester hydrochloride | 220060-08-2 | / | / |
| 2-Iodo-5-methoxybenzoic acid | 54413-93-3 | / | / |
| 5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoic acid | 1293284-55-5 | / | / |
| 1H-Benzimidazole, 6-chloro-7-methyl-2-[(2S)-2-methyl-2-pyrrolidinyl]-, hydrochloride (1:1) | 1788104-76-6 | / | / |
| (S)-1-(tert-butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid | 103336-06-7 | / | / |
| (S)-2-Methylpyrrolidine-2-carboxylic acid hydrochloride | 1508261-86-6 | / | / |
| 6-Chloro-2,3-diaminotoluene | 673487-36-0 | / | / |
| 4-Chloro-3-Methylbenzene-1,2-diaMine hydrochloride | 1087743-89-2 | / | / |
Building toward Nemorexant?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →